Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background: Overweight and obesity affect health, quality of life and ability to work. Therefore, the scientifically evaluated program "SHAPE AND MOTION - medically ◦ accompanied ◦ slimming" was developed to support overweight and obese people in weight loss.
Method: In a randomized controlled clinical trial, the effect of a lifestyle intervention with meal replacement by formula diet, exercise stimulation, and telemedicine coaching is examined compared to a control group with routine care. The learning contents are taught in 7 group trainings, a practical unit with shopping and cooking training, as well as in 4 individual telephone conversations. The state of health is examined at the beginning, after 12 and 26 weeks.
Objective: The aim is to develop a training and counseling program for overweight or obese individuals with diabetes risk or type 2 diabetes, which can be used both for primary and for tertiary prevention of overweight-related diseases.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group | Experimental | Lifestyle intervention with meal replacement by formula diet, exercise stimulation, and telemedicine coaching. |
|
| Control group | No Intervention | Routine care. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lifestyle intervention | Combination Product | Meal replacement by formula diet, exercise stimulation, and telemedicine coaching. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Weight loss in kg | Estimated treatment difference | 26 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| body mass index in kg/m2 | Estimated treatment difference | 26 weeks |
| waist circumference in cm | Estimated treatment difference | 26 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stephan Martin, MD | West-German Centre of Diabetes and Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| West-German Centre of Diabetes and Health | Düsseldorf | 40591 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050177 | Overweight |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| hip circumference in cm | Estimated treatment difference | 26 weeks |
| fat mass in kg | Estimated treatment difference | 26 weeks |
| lean body mass in kg | Estimated treatment difference | 26 weeks |
| muscle mass in kg | Estimated treatment difference | 26 weeks |
| energy expenditure in kcal | Estimated treatment difference | 26 weeks |
| blood pressure in mmHg | Estimated treatment difference | 26 weeks |
| quality of life (sf-12 questionnaire) in units on a scale | Estimated treatment difference | 26 weeks |
| depression (German version of the Center for Epidemiological Studies-Depression [CES-D] Scale) in units on a scale | Estimated treatment difference | 26 weeks |
| physical activity in min/day | Estimated treatment difference | 26 weeks |
| physical activity in steps/day | Estimated treatment difference | 26 weeks |
| eating behaviour (German version of the Three-factor Eating Questionnaire [TFEQ]) in units on a scale | Estimated treatment difference | 26 weeks |
| total cholesterol in mg/dl | Estimated treatment difference | 26 weeks |
| HDL cholesterol in mg/dl | Estimated treatment difference | 26 weeks |
| LDL cholesterol in mg/dl | Estimated treatment difference | 26 weeks |
| triglycerides in mg/dl | Estimated treatment difference | 26 weeks |
| fasting blood glucose in mg/dl | Estimated treatment difference | 26 weeks |
| insulin in µU/ml | Estimated treatment difference | 26 weeks |
| HbA1c in % | Estimated treatment difference | 26 weeks |
| uric acid in mg/dl | Estimated treatment difference | 26 weeks |
| creatinin in mg/dl | Estimated treatment difference | 26 weeks |
| medication in mg/day | Estimated treatment difference | 26 weeks |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |